NEW YORK – Antelope Dx announced Wednesday it received a €2.5 million ($2.8 million) grant from the Flanders Agency for Innovation and Entrepreneurship (VLAIO) to develop its home-based testing diagnostic device.
The money will be used to develop the company's point-of-care device and diagnostic test, which will be a urine-based self-test to check for sexually transmitted bacterial infections Chlamydia trachomatis and Neisseria gonorrhoeae.
The Belgium-based company was spun out from Mycartis in July and said it hopes its device will offer clinical lab performance with the ease of use and price of a consumer pregnancy test. In its first equity round, the company raised €5.1 million.
“There are very few diagnostic solutions that allow concerned individuals and patients to test their health condition at home," said the company's CEO, Hilde Windels. "This VLAIO grant validates our approach to take diagnostics in the discrete home setting where both therapy monitoring and acute infectious disease testing will be possible."